Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

Diamond Equity Research Update 26 Jun 2024 – Radiopharm Extends Runway to Key Inflection Points

Friday, June 28, 2024 1 min read
Key Takeaway: Radiopharm Theranostics has announced significant progress, including the extension of its operational runway to key inflection points. The company has received IND approval from the US FDA to initiate a Phase I therapeutic clinical study targeting B7H3 with its product BetaBart (RV-01). Additionally, positive updates were shared across four clinical programs.

Market Sentiment Analysis

POSITIVE FACTORS

  • Radiopharm Theranostics has extended its runway to key inflection points.
  • The company received IND approval from the US FDA for a new therapeutic study.
  • Positive clinical updates were provided across four programs.

Full Press Release Details

• Updates
• PDF
• June 28, 2024
Loading Viewer…

More Announcements & Updates

• Announcements
• December 13, 2022
• Announcements
• April 28, 2023
• Announcements
• July 17, 2024
• Announcements , Updates
• October 20, 2025

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What recent updates did Radiopharm announce?

Radiopharm announced the extension of its operational runway and received FDA IND approval.

What is BetaBart (RV-01)?

BetaBart (RV-01) is a therapeutic product targeting B7H3 in a Phase I clinical study.

How many clinical programs received updates?

Positive updates were provided across four clinical programs.

Who was appointed to the advisory board?

Dr. Oliver Sartor was appointed to Radiopharm's Scientific Advisory Board.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm BetaBart FDA approval clinical study B7H3
Last updated: Jun 28, 2024